Exelixis (EXEL) Beats Q2 Earnings Estimates

分组1 - Exelixis reported quarterly earnings of $0.75 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, but down from $0.84 per share a year ago, resulting in an earnings surprise of +15.38% [1] - The company posted revenues of $568.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 1.84% and down from $637.18 million year-over-year [2] - Exelixis has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 36.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.6% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the upcoming quarter is $0.69 on revenues of $594.62 million, and for the current fiscal year, it is $2.65 on revenues of $2.35 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Exelixis belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook for the sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]